Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatme...( - Emphysema and chronic bronchit...)

- Emphysema and chronic bronchitis patients to benefit from rapid, long-lasting symptom control with twice-daily dosing of first nebulized

formoterol fumarate -

NAPA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), today announced the launch of Perforomist(TM) (formoterol fumarate) Inhalation Solution, which will be available nationwide through retail pharmacies, hospitals, long-term care facilities, and home healthcare companies. Perforomist(TM) Inhalation Solution is indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

The formoterol molecule is a rapid and long-acting beta2-agonist (LABA) that has been previously available in the U.S. in a dry powder formulation and has twenty years of worldwide experience. Perforomist(TM) Inhalation Solution is the first and only FDA-approved nebulized form of this molecule. Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or face mask.

"In treating patients with moderate to advanced COPD, I have found LABAs to be very effective, and in particular I think formoterol provides excellent long-term symptom control," said Donald P. Tashkin, MD, FACP, FCCP, Professor of Medicine, David Geffen School of Medicine at the University of California at Los Angeles. "Since patients have difficulty adhering to complicated medication regimens, it's very helpful that Perforomist(TM) Inhalation Solution offers a twice-daily nebulized version of formoterol. I consider nebulization to be an especially effective way to deliver medication into
'/>"/>